Insights into Male Breast Cancer: A Clinicopathological Study of Cases in Assam, India
Published: 2024-05-30
Page: 292-299
Issue: 2024 - Volume 7 [Issue 1]
Likuma Das *
Department of General Surgery, Assam Medical College and Hospital, India.
Diganta Borgohain
Department of General Surgery, Assam Medical College and Hospital, India.
Uttam Konwar
Department of General Surgery, Assam Medical College and Hospital, India.
Razvi Das
Department of General Surgery, Assam Medical College and Hospital, India.
*Author to whom correspondence should be addressed.
Abstract
Background: Male Breast Cancer is a rare disease, which accounts for less than 1% of breast cancer. Common risk factors are radiation exposure and estrogen therapy whereas the commonest presentation is palpable breast lump. Triple assessment forms the basis of diagnosis. Modified Radical Mastectomy is the treatment of choice usually followed by adjuvant chemotherapy.
Aims: To evaluate the clinico-pathological and immunohistochemical characteristics of Male Breast Carcinoma.
Study Design: A retrospective multicentric observational study.
Place and Duration of Study: A duration of 18 months from January 2022 to June 2023 in two tertiary level hospitals of Assam.
Methodology: A retrospective multicentric observational study is performed in Assam. The patients are ascertained from hospital admission register over a period of 18 months from January 2022 to June 2023. The patients contact numbers are retrieved and data are collected along with details of recurrence and death. The associations between clinical factors, pathological status and treatment choice are reviewed in cross- tabulation form.
Results: Nine patients of MBC are studied over a period of 18months. The median age of presentation is 45years.The most common presentation is palpable lump around nipple areolar complex. Cases of fungating mass are also seen. On USG analysis, 66% patients have BIRADS IV lesion with axillary lymphadenopathy in 89% patients. HPE reports suggested Invasive Ductal Carcinoma in 89% cases. ER positivity is observed in 80%, PR positivity 70% and Her2 neu positivity in 20% cases. Treatment options include modified radical mastectomy along with chemotherapy and radiotherapy. Overall mortality is found to be 20%.
Conclusion: Male Breast Cancer is found to be more aggressive than Female Breast Cancer. The important prognostic factors are tumour size, nodal involvement, histological grade and hormone receptor status which is similar to female breast cancer. Treatment options are similar to that of FBC. Breast carcinoma awareness in the community, early detection and timely management of the disease are the keys for improvement of its prognosis.
Keywords: Male breast cancer, clinico-pathological, immuno-histopathological, BIRADS, modified radical mastectomy
How to Cite
Downloads
References
Schwartz’s textbook of Surgery 11th edition.
Sabiston textbook of Surgery 20th edition.
Bailey and Love’s short practice of Surgery 28th edition.
Male Breast Carcinoma: A Clinical and Pathological Review: Sara Javidiparsijani, MD1, Lauren E. Rosen, MD2 and Paolo Gattuso, MD1. 2016.
Unraveling Stigmas of Male Breast Carcinoma: A Singular Case of Advanced Metaplastic Breast Carcinoma in a Young Male. Muhammad Awais Kanwal, Umaisa Khalid, and et al. 2023.
Hereditary breast cancer: syndromes, tumour pathology and molecular testing, A Sokolova,K J Johnstone,A E McCart Reed,P T Simpson,S R Lakhani. 2022.
Targeting signalling pathways and the immune microenvironment of cancer stem cells—A clinical update JA Clara, C Monge, Y Yang, N Takebe, nature.com 2020.
Male breast cancer risk associated with pathogenic variants in genes other than BRCA1/2: an Italian case-control study by Agostino Bucalo, Giulia Conti, Virginia Valentini, Carlo Capalbo. DOI:org/10.1016/j.ejca.2023.04.022.
Epidemiology of male breast cancer by Santhi Konduri, Maharaj Singh, George Bobustuc, Richard Rovin, Amin Kassam February 2020.
Fasoulakis Z, Kolios G, Papamanolis V, Kontomanolis EN. Interleukins Associated with Breast Cancer. Cureus. 2018; 10(11):e3549. DOI:10.7759/cureus.3549. PMID: 30648081; PMCID: PMC6324869.
Yildiz S, Bayil Oguzkan S, Ozaslan M, Kizikli A, Halil Kilic I, Yilmaz M. Interleukin-6 And Interleukin-10 Polymorphisms In Chronic Lymphoid Leukemia Patients. Asian Pacific Journal of Cancer Prevention; 2024.
Niculet E, Chioncel V, Elisei AM, Miulescu M, Buzia OD, Nwabudike LC, Craescu M, Draganescu M, Bujoreanu F, Marinescu E, Arbune M, Radaschin DS, Bobeica C, Nechita A, Tatu AL. Multifactorial expression of IL-6 with update on COVID-19 and the therapeutic strategies of its blockade (Review). Exp Ther Med. 2021.
Multifactorial expression of IL-6 with update on COVID-19 and the therapeutic strategies of its blockade (Review). Exp Ther Med; 2021.
Sequencing of Interleukins4, 13, 31, and 33 - An Integrated Systematic Review: Dermatological and Multidisciplinary Perspectives. J Inflamm Res; 2022.
Mihailov R, Tatu AL, Niculet E, et al. A narrative review of cutaneous manifestations and imaging landmarks of breast cancer; 2024.
Cutaneous lesions as the first manifestation of breast cancer: a rare case. Harwin Prestasia Putra, Khairuddin Diawad, Airin Riskianty Nurdin; 2020.
Pleomorphic Appearance of Breast Cancer Cutaneous Metastases, Alexander Muacevic and John R Adler Philip R Cohen; 2021.
An unusual cutaneous manifestation of inflammatory breast carcinoma, Sherin Jose, Anila Nitin and et al, Government Medical College, Kottayam, Kerala; 2020.
A review of the management of the male breast carcinoma based on an analysis of 420 treated cases: G. G. Ribeiro, R. Swindell, M. Harris, S. S. Banerjeet and A. Cramert The Christie Hospital Trust, Manchester, UK.